Therapeutic indications

Afamelanotide is indicated for:

Prevention of phototoxicity in erythropoietic protoporphyria (EPP)

Irrespective of gender only Adults (18 - 65 years old)

Afamelanotide is indicated for prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Subcutaneous - 16 mg once every 2 months


Active ingredient Afamelanotide is contraindicated in the following cases:

Hepatic impairment

Renal impairment

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines